Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53^± murine model

References

• Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garssen J, Velayati A, Adcock IM. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365. doi:10.3389/fimmu.2016.00365.
   PubMed Web of Science ®Google Scholar
• Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J, Mizutani S, Ochs HD, Nonoyama S. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–464. doi:10.1182/blood-2003-05-1480.
   PubMed Web of Science ®Google Scholar
• Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876–885. doi:10.1016/S0022-3476(05)82002-5.
   PubMed Web of Science ®Google Scholar
• Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22:261–281. doi:10.1016/j.blre.2008.03.009.
   PubMed Web of Science ®Google Scholar
• Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, George B. Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature. Indian J Hematol Blood Transfus. 2014;30:309–313. doi:10.1007/s12288-014-0377-1.
   PubMed Web of Science ®Google Scholar
• Du S, Scuderi R, Malicki DM, Willert J, Bastian J, Weidner N. Hodgkin’s and non-Hodgkin’s lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatr Dev Pathol: Off J Soc Pediatr Pathol Paediatric Pathol Soc. 2011;14:64–70. doi:10.2350/10-01-0787-CR.1.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res. 1992;52:5465s–7s.
   PubMed Web of Science ®Google Scholar
• Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28:1263–1269.
   PubMed Web of Science ®Google Scholar
• Worth AJ, Thrasher AJ. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev Clin Immunol. 2015;11:1015–1032. doi:10.1586/1744666X.2015.1062366.
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Kamachi Y, Imai K, Watanabe N, Nakadate H, Kanazawa T, Ozono S, Kobayashi R, Yoshida M, Kobayashi C, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer. 2013;60:836–841. doi:10.1002/pbc.v60.5.
   PubMed Web of Science ®Google Scholar
• Beel K, Cotter MM, Blatny J, Bond J, Lucas G, Green F, Vanduppen V, Leung DW, Rooney S, Smith OP, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene. Br J Haematol. 2009;144:120–126. doi:10.1111/bjh.2008.144.issue-1.
   PubMed Web of Science ®Google Scholar
• Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, Van Den Oord JJ, Verhoef GEG, Boogaerts MA, Fryns J-P, You D, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313–317. doi:10.1038/85886.
   PubMed Web of Science ®Google Scholar
• Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood. 2006;108:2182–2189. doi:10.1182/blood-2006-01-010249.
   PubMed Web of Science ®Google Scholar
• Moulding DA, Blundell MP, Spiller DG, White MR, Cory GO, Calle Y, Kempski H, Sinclair J, Ancliff PJ, Kinnon C, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med. 2007;204:2213–2224. doi:10.1084/jem.20062324.
   PubMed Web of Science ®Google Scholar
• Westerberg LS, Meelu P, Baptista M, Eston MA, Adamovich DA, Cotta-de-Almeida V, Seed B, Rosen MK, Vandenberghe P, Thrasher AJ, et al. Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. J Exp Med. 2010;207:1145–1152. doi:10.1084/jem.20091245.
   PubMed Web of Science ®Google Scholar
• Moulding DA, Moeendarbary E, Valon L, Record J, Charras GT, Thrasher AJ. Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacity. Blood. 2012;120:3803–3811. doi:10.1182/blood-2012-03-419663.
   PubMed Web of Science ®Google Scholar
• Coppe A, Nogara L, Pizzuto MS, Cani A, Cesaro S, Masetti R, Locatelli F, Te Kronnie G, Basso G, Bortoluzzi S, et al. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Hum Mutat. 2018;39:579–587. doi:10.1002/humu.23399.
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221. doi:10.1038/356215a0.
   PubMed Web of Science ®Google Scholar
• Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet. 1994;8:66–69. doi:10.1038/ng0994-66.
   PubMed Web of Science ®Google Scholar
• Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res. 1995;55:3883–3889.
   PubMed Web of Science ®Google Scholar
• Lee JM, Abrahamson JL, Kandel R, Donehower LA, Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 1994;9:3731–3736.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010;24:1389–1402. doi:10.1101/gad.1940710.
   PubMed Web of Science ®Google Scholar
• Adams CM, Eischen CM. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer. Cancer Res. 2014;74:3923–3934. doi:10.1158/0008-5472.CAN-13-1866.
   PubMed Web of Science ®Google Scholar
• Safran M, Kim WY, O’Connell F, Flippin L, Gunzler V, Horner JW, DePinho RA, Kaelin WG. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA. 2006;103:105–110. doi:10.1073/pnas.0509459103.
   PubMed Web of Science ®Google Scholar
• Gupta D, Shah HP, Malu K, Berliner N, Gaines P. Differentiation and characterization of myeloid cells. Curr Protoc Immunol. 2014;104:Unit 22F 5.
   PubMedGoogle Scholar
• Bottai M, Zhang J. Laplace regression with censored data. Biom J Biometrische Zeitschrift. 2010;52:487–503. doi:10.1002/bimj.200900310.
   PubMed Web of Science ®Google Scholar
• Lacroix-Triki M, Lacoste-Collin L, Jozan S, Charlet JP, Caratero C, Courtade M. Histiocytic sarcoma in C57BL/6J female mice is associated with liver hematopoiesis: review of 41 cases. Toxicol Pathol. 2003;31:304–309. doi:10.1080/01926230390204342.
   PubMed Web of Science ®Google Scholar
• Singh P, Coskun ZZ, Goode C, Dean A, Thompson-Snipes L, Darlington G. Lymphoid neogenesis and immune infiltration in aged liver. Hepatology (Baltimore, Md). 2008;47:1680–1690. doi:10.1002/hep.22224.
   PubMed Web of Science ®Google Scholar
• Gostissa M, Bianco JM, Malkin DJ, Kutok JL, Rodig SJ, Morse HC 3rd, Bassing CH, Alt FW. Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proc Natl Acad Sci USA. 2013;110:2934–2939. doi:10.1073/pnas.1222570110.
   PubMed Web of Science ®Google Scholar
• Catucci M, Zanoni I, Draghici E, Bosticardo M, Castiello MC, Venturini M, Cesana D, Montini E, Ponzoni M, Granucci F, et al. Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity. Eur J Immunol. 2014;44:1039–1045. doi:10.1002/eji.201343935.
   PubMed Web of Science ®Google Scholar
• Orange JS, Roy-Ghanta S, Mace EM, Maru S, Rak GD, Sanborn KB, Fasth A, Saltzman R, Paisley A, Monaco-Shawver L, et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest. 2011;121:1535–1548. doi:10.1172/JCI44862.
   PubMed Web of Science ®Google Scholar
• Kritikou JS, Dahlberg CI, Baptista MA, Wagner AK, Banerjee PP, Gwalani LA, Poli C, Panda SK, Kärre K, Kaech SM, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636. doi:10.1038/srep30636.
   PubMed Web of Science ®Google Scholar
• De Meester J, Calvez R, Valitutti S, Dupre L. The Wiskott-Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets. J Leukoc Biol. 2010;88:1031–1040. doi:10.1189/jlb.0410197.
   PubMed Web of Science ®Google Scholar
• Ishihara D, Dovas A, Hernandez L, Pozzuto M, Wyckoff J, Segall JE, Condeelis JS, Bresnick AR, Cox D. Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Rep. 2013;4:429–436. doi:10.1016/j.celrep.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Reviews Immunol. 2010;10:182–192. doi:10.1038/nri2724.
   PubMed Web of Science ®Google Scholar